Ridinilazole for the treatment of Clostridioides difficile infection

ABSTRACT

Introduction: Ridinilazole is a novel antibiotic being developed for the treatment of Clostridioides difficile infection (CDI). Ridinilazole has completed two phase II trials and phase III trials which are denoted Ri-CoDIFy 1 and 2, are planned (ClinicalTrials.gov identifiers: NCT03595553 and NCT03595566).

Areas covered: This article covers the chemistry, mechanism of action, in vitro microbiology versus C. difficile and host microbiota, pre-clinical and clinical efficacy, pharmacokinetics, pharmacodynamics and safety and tolerability of ridinilazole.

Expert opinion: Ridinilazole is a novel antibiotic with ideal properties for the treatment of CDI. Given the promising results from the phase II clinical trial, ridinilazole may have the capability to lower the risk for CDI recurrence thus improving sustained clinical response rates – a current unmet medical need. Assuming a positive phase III trial, ridinilazole will enter a market with heightened awareness on the importance of prevention of CDI. This along with further research into the economic consequences and decreased patient quality of life associated with recurrent CDI, should provide clinicians with further evidence for the need for therapy that limits CDI recurrence and improves sustained clinical cure.

Trial registration: ClinicalTrials.gov identifier: NCT03595553.

Trial registration: ClinicalTrials.gov identifier: NCT03595566.

Trial registration: ClinicalTrials.gov identifier: NCT03595553.

Trial registration: ClinicalTrials.gov identifier: NCT03595566.

KEYWORDS:

• CDI
• clostridium difficile
• Clostridioides difficile
• diarrhea
• ridinilazole
• SMT19969
• vancomycin

Box 1. Drug summary

Declaration of interest

KW Garey has received research funding from Summit Therapeutics and Merck & Co. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.